Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 8/20 | 0.57 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.57 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | METAP1 | P53582 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28311596 | 0.85 | CYP24A1 (0.52) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL13039619 | 0.80 | DRD2 (0.60) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL7519184 | 0.79 | CYP24A1 (0.54) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL630841 | 0.79 | ACHE (0.58) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL7271049 | 0.79 | CYP24A1 (0.56) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL7135478 | 0.79 | CYP19A1 (0.49) | CYP19A1DRD2HTR2C | |
| SCHEMBL4098450 | 0.79 | CYP24A1 (0.54) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL5753017 | 0.78 | CYP24A1 (0.55) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL22867686 | 0.78 | CYP24A1 (0.55) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL3587277 | 0.78 | CYP24A1 (0.55) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963292-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-7700633-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20080262050-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1963292-A2 | ORGANIC COMPOUNDS | Novartis Pharma AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067615-A2 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262050-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | CYP24A1 3784/4885CYP27A1 948/4885CYP26A1 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.